Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial
The world's most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
MAPS in the Media
Second MAPS-Sponsored Phase 3 Trial of MDMA-Assisted Therapy for PTSD Completed
FOR IMMEDIATE RELEASE: November 17, 2022 MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase …
Psychoactive: Rick Doblin on a Life in Psychedelics Advocacy
Rick Doblin founded the Multidisciplinary Association for Psychedelic Studies (MAPS) in 1986, and we’ve been friends since shortly thereafter. He and his organization stand at the forefront of the movement …
The New York Times: A Balm for Psyches Scarred by War
Summary: The New York Times publishes an investigative article exploring the impact of PTSD and moral injury in Veterans, highlighting published data from MAPS-sponsored clinical trials of MDMA-assisted …
Participant Experiences & “Cover Story”
We encourage you to read and follow maps.org/safety for detailed information regardingMAPS Code of Ethics for Psychedelic Psychotherapyand our practices to create a culture of safety in psychedelic therapy. …
Results for Phase 1 Randomized Controlled Trial of MDMA and Fear Extinction Retention in Healthy Adults Published in Psychopharmacology
On February 15, 2022, the results of our evaluation of MDMA on the startle response in healthy adults was published in the medical journal Psychopharmacology. This randomized, blinded, placebo-controlled …
Results for Phase 1 Randomized Controlled Trial of MDMA and Fear Extinction Retention in Healthy Adults Published in Psychopharmacology
On February 15, 2022, the results of the MAPS-sponsored study by Barbara Rothbaum and team at Emory University evaluating MDMA on the startle response in healthy adults was published in the medical journal …
Science: MDMA-Assisted Therapy Selected as Runner-Up in Breakthrough of the Year
Summary: MAPS is thrilled to receive recognition for our cutting-edge research from one of the world’s top academic journals, especially given our complicated history! In 2003, Science retracted …
Lucid News: Rick Doblin Explains MAPS’ New $70 Million Investment Fund With Vine Ventures
Summary: In an interview with Lucid News, MAPS Founder and Executive Director Rick Doblin, Ph.D., explains MAPS’ innovative $70 million regenerative financing structure with Vine Ventures, which …
ABC Radio National: All in the Mind Podcast: Psychedelics for Mental Illness with Rick Doblin, Ph.D.
Summary: On ABC Radio National’s All in the Mind podcast, MAPS Founder and Executive Director Rick Doblin, Ph.D., explains the results of MAPS’ first Phase 3 clinical trial of MDMA-assisted therapy …
Bloomberg: Jurvetson’s Big Gift Shows How Psychedelics Capital Is Different
Summary: In an article covering unique and innovative approaches to funding psychedelic research, Bloomberg highlights the perspective shared by MAPS Public Benefit Corporation (MAPS PBC) CEO Amy Emerson …
MAPS and Vine Ventures Pioneer Novel Regenerative Funding Structure to Infuse Psychedelic-Assisted Therapy Research and Access With Timely $70 Million
Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once …